Weiguo Ye
About Weiguo Ye
Weiguo Ye, 48, is Chief Operating Officer of Gyre Therapeutics (since October 2023) and Director/President of majority-owned subsidiary Gyre Pharmaceuticals (since April 2023). He has 20+ years in pharma commercial and operations leadership, with prior roles at Shanghai Roche, Simcere, and Hubei Monyan; education includes an executive MBA from CEIBS (2021) and an undergraduate diploma in applied pharmacy from Peking University (2009) . During his tenure window, company pay-versus-performance disclosures show FY2024 net income of $17.9M vs. ($85.5M) in 2023 and cumulative TSR index of 134 in 2024 (base=100 at 12/31/2021), framing improving profitability though TSR remains below 2023 levels .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| Gyre Therapeutics (Gyre Pharmaceuticals subsidiary) | Director and President | Apr 2023–present | Overall management and operations of Gyre Pharmaceuticals |
| Gyre Pharmaceuticals | Chief Operating Officer | Jan 2021–Apr 2023 | Senior operating leadership prior to becoming President |
| Gyre Pharmaceuticals | Executive Vice President | May 2018–Apr 2023 | Progressively broader operating remit |
| Gyre Pharmaceuticals | Vice President | Sep 2017–May 2018 | Commercial/operations leadership |
| Gyre Pharmaceuticals | Sales Director | Dec 2016–Sep 2017 | Sales leadership |
| Hubei Monyan Pharmaceuticals | Marketing Vice President | Mar 2015–Nov 2016 | Commercial leadership |
| Jiangsu Simcere Pharmaceutical | Grand Area Manager → National Sales Director | Nov 2011–Feb 2015 | National sales leadership |
| Shanghai Roche Pharmaceutical | Various; last role: Regional Sales Manager | Aug 1997–Nov 2011 | Long-tenured commercial leadership |
External Roles
- No external public-company directorships or outside roles were disclosed for Mr. Ye in the executive officers section of the 2025 proxy .
Fixed Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Base salary paid ($) | 265,656 | 148,279 |
| Base salary rate at year-end ($) | — | 150,000 (as of 12/31/2024) |
| Target bonus % | — | Not disclosed for Ye; program is performance-based |
| Actual cash bonus/non-equity incentive ($) | — | 168,499 |
| All other compensation ($) | 8,961 (statutory pension contributions) | 15,841 (statutory pension contributions) |
| Total ($) | 274,617 | 332,619 |
Notes:
- Mr. Ye is party to a standard labor contract with Gyre Pharmaceuticals providing a monthly base salary and standard welfare/retirement benefits; no individualized bonus target % was specified for him, though he received variable compensation for 2024 performance .
Performance Compensation
Annual Incentive (Cash)
| Metric framework | Weighting | Target | Actual | Payout ($) | Vesting/Timing |
|---|---|---|---|---|---|
| Company and personal goals under cash-based incentive program | Not disclosed | Not disclosed | Not disclosed | 168,499 | Paid for FY2024 performance; program tied to pre-defined business and personal objectives set by the Compensation Committee |
Equity Awards (Options/RSUs/PSUs)
| Award type | Grant date | Shares/Units | Exercise/Grant price ($) | Vesting schedule | Status | Expiration |
|---|---|---|---|---|---|---|
| Stock options (replacement award) | 10/30/2023 | 1,665,115 | 0.75 | Fully vested replacement options issued shortly after business combination | Fully exercisable | 10/29/2030 |
| RSUs/PSUs | — | — | — | — | None disclosed for Ye | — |
Notes:
- The 10/30/2023 option grant represents fully vested replacement Company stock options in respect of previously outstanding options to purchase shares of Gyre Pharmaceuticals; therefore no future vesting-related selling pressure is embedded in this grant .
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Total beneficial ownership | 1,677,615 shares underlying options exercisable within 60 days; no direct share ownership disclosed |
| Ownership as % of outstanding | 1.8% (1,677,615 vs. 93,612,442 shares outstanding as of Mar 12, 2025) |
| Vested vs. unvested | Options exercisable: 1,677,615; Unexercisable: 0; No RSUs/PSUs disclosed |
| Option details | Exercise price $0.75; expiration 10/29/2030 |
| Stock ownership guidelines | The proxy discloses insider trading and clawback policies, but does not include executive stock ownership guidelines; none were referenced for executives in the governance section reviewed . |
| Hedging/pledging | Insider trading policy prohibits short-term trading, short sales, and trading in derivatives/hedging; no explicit pledging policy was described in the cited section . |
| Clawback | Nasdaq 5608-compliant restatement-recovery policy covering incentive-based compensation received after 10/30/2023 and during prior three fiscal years . |
Employment Terms
| Term | Disclosure |
|---|---|
| Employment basis | Standard labor contract with Gyre Pharmaceuticals (monthly base salary; standard welfare/retirement benefits) |
| Severance | No individualized severance provisions disclosed for Mr. Ye; severance/change-in-control economics summarized only for CEO and CFO . |
| Non-compete / non-solicit | Not disclosed for Mr. Ye; non-solicit disclosed only for CEO/CFO agreements . |
| Start in current roles | COO, Gyre Therapeutics: Oct 2023; Director/President, Gyre Pharmaceuticals: Apr 2023 |
| Tenure in company group | Progressively senior roles at Gyre Pharmaceuticals since 2016 |
Investment Implications
- Pay-for-performance alignment and metrics transparency: Ye’s 2024 variable pay was sizable ($168.5K), but specific performance metrics/weights were not disclosed; this limits visibility into cash bonus rigor even though the program references company/personal goals . The clawback policy mitigates restatement-related risk on incentive pay .
- Potential selling pressure from equity: Ye holds a large fully vested option block (1.67M options, $0.75 strike, expiring 2030). While we cannot assess in-the-money value without current price, the full vesting means potential supply is unconstrained by service-based vesting; exercise/monetization timing will depend on blackout windows and personal decisions .
- Alignment via ownership: Beneficial ownership consists entirely of exercisable options with no disclosed direct share ownership; the proxy provides no executive stock ownership guidelines or pledging policy disclosure in the cited sections, offering limited assurance on long-term “skin-in-the-game” and collateralization risk beyond the general insider trading prohibitions on hedging/derivatives .
- Retention risk: Unlike the CEO/CFO, Ye’s standard labor contract does not include severance/change-in-control protections, suggesting lower contractual retention economics; however, his significant vested option position provides ongoing equity-linked incentive to remain and support value creation .
- Operating track record context: Company-level pay-versus-performance shows a swing to positive net income in 2024 and a TSR index of 134 for 2024 (base 100 at 12/31/2021). As COO since late 2023, Ye’s tenure overlaps the improvement in profitability, but the TSR level remains below 2023’s index, so external return signals are mixed .
Sources
- Gyre Therapeutics, Inc. DEF 14A (filed 2025-04-21): Executive officers; background and education ; Executive compensation tables and narratives ; Governance, clawback, and insider trading policies ; Security ownership, shares outstanding ; Pay-versus-performance metrics incl. TSR and net income .